Patents by Inventor Jonathan Gareth Williams
Jonathan Gareth Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8642773Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers, which is an inhibitor of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.Type: GrantFiled: April 1, 2010Date of Patent: February 4, 2014Assignee: Respivert Ltd.Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Onions, Catherine Elisabeth Charron
-
Patent number: 8618140Abstract: There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.Type: GrantFiled: September 14, 2012Date of Patent: December 31, 2013Assignee: Respivert LtdInventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Thomas Onions, Simon Christopher Hirst, David Michel Adrien Taddei, Catherine Elisabeth Charron
-
Publication number: 20130156826Abstract: The present invention relates to respiratory formulations comprising a compound of formula (I): and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I).Type: ApplicationFiled: June 17, 2011Publication date: June 20, 2013Applicant: Respivert LimitedInventors: Peter John Murray, Stuart Thomas Onions, Jonathan Gareth Williams, Kevin Joly
-
Publication number: 20130040995Abstract: There is provided inter alia a compound of formula (I): wherein R1, J, Ar, L, X, R3 and R4 are as defined in the specification, for use in the treatment of inflammatory disorders.Type: ApplicationFiled: April 8, 2011Publication date: February 14, 2013Inventors: John King-Underwood, Kazuhiro Ito, Peter Strong, William Garth Rapeport, Catherine Elisabeth Charron, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
-
Publication number: 20130040962Abstract: There is provided a compound of formula (I): wherein: J represents (A): or (B): compositions comprising same, processes for preparing said compounds and use thereof in treatment, particularly in the treatment of inflammatory disease, such as asthma, COPD and 15 rheumatoid arthritis.Type: ApplicationFiled: April 8, 2011Publication date: February 14, 2013Inventors: John King-Underwood, Peter John Murray, Jonathan Gareth Williams, Ildiko Buck, Stuart Thomas Onions
-
Publication number: 20130029990Abstract: There are provided inter alia compounds of formula (I): wherein R1, R2a, R2b, R3, R4, L, X, R5 and R6 are as defined in the description for use in the treatment of inflammatory diseases.Type: ApplicationFiled: April 1, 2011Publication date: January 31, 2013Inventors: John King-Underwood, George Hardy, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
-
Publication number: 20130012512Abstract: There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Thomas Onions, Simon Christopher Hirst, David Michel Adrien Taddei, Catherine Elisabeth Charron
-
Patent number: 8299073Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof, which are inhibitors of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.Type: GrantFiled: December 11, 2009Date of Patent: October 30, 2012Assignee: Respivert Ltd.Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Thomas Onions, Simon Christopher Hirst, David Michel Adrien Taddei, Catherine Elisabeth Charron
-
Patent number: 8299074Abstract: The present disclosure relates to compounds of formula (I): which are inhibitors of p38 mitogen-activated protein kinase enzymes, particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.Type: GrantFiled: December 11, 2009Date of Patent: October 30, 2012Assignee: RespiVert Ltd.Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Thomas Onions, Kevin Joly, Catherine Elisabeth Charron
-
Patent number: 8293771Abstract: There is provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, including all tautomers thereof, compositions comprising the same, use of said compound and compositions for treatment, in particular for the treatment of asthma and COPD, and processes for the preparation of said compound.Type: GrantFiled: October 2, 2009Date of Patent: October 23, 2012Assignee: Respivert Ltd.Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, John King-Underwood, Jonathan Gareth Williams, Stuart Thomas Onions, Peter John Murray, Catherine Elisabeth Charron
-
Patent number: 8293748Abstract: There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.Type: GrantFiled: October 2, 2009Date of Patent: October 23, 2012Assignee: Respivert Ltd.Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Thomas Onions, Simon Christopher Hirst, David Michel Adrien Taddei, Catherine Elisabeth Charron
-
Publication number: 20120136031Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers, which is an inhibitor of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.Type: ApplicationFiled: April 1, 2010Publication date: May 31, 2012Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Onions, Catherine Elisabeth Charron
-
Publication number: 20110312963Abstract: The present disclosure relates to compounds of formula (I): which are inhibitors of p38 mitogen-activated protein kinase enzymes, particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPDType: ApplicationFiled: December 11, 2009Publication date: December 22, 2011Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Thomas Onions, Kevin Joly, Catherine Elisabeth Charron
-
Publication number: 20110294812Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof, which are inhibitors of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.Type: ApplicationFiled: December 11, 2009Publication date: December 1, 2011Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Thomas Onions, Simon Christopher Hirst, David Michel Adrien Taddei, Catherine Elisabeth Charron
-
Publication number: 20110269800Abstract: There is provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, including all tautomers thereof, compositions comprising the same, use of said compound and compositions for treatment, in particular for the treatment of asthma and COPD, and processes for the preparation of said compound.Type: ApplicationFiled: October 2, 2009Publication date: November 3, 2011Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, John King-Underwood, Jonathan Gareth Williams, Stuart Thomas Onions, Peter John Murray, Catherine Elisabeth Charron
-
Publication number: 20110212962Abstract: There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.Type: ApplicationFiled: October 2, 2009Publication date: September 1, 2011Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Thomas Onions, Simon Christopher Hirst, David Michel Adrien Taddei, Catherine Elisabeth Charron
-
Patent number: 8003695Abstract: Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH—Y-L1-X1—(CH2)z— wherein: z is 0 or 1; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(?O)—, —S(?P)2-, —C(?O)O—, —C(?O)NR3-, —C(?S)—NR3, —C(?NH)—NR3 or —S(?O)2NR3— wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L is a divalent linker radical of formula -(Alk1)m(Q)(Alk2)p- wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.Type: GrantFiled: October 29, 2007Date of Patent: August 23, 2011Assignee: Chroma Therapeutics Ltd.Inventors: David Festus Charles Moffat, Stephen John Davies, Michael Hugh Charlton, Simon Christopher Hirst, Stuart Thomas Onions, Jonathan Gareth Williams
-
Publication number: 20100087515Abstract: Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH—Y-L1-X1—(CH2)z— wherein: z is 0 or 1; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(?O)—, —S(?P)2-, —C(?O)O—, —C(?O)NR3-, —C(?S)—NR3, —C(?NH)—NR3 or —S(?O)2NR3— wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L is a divalent linker radical of formula -(Alk1)m(Q)(Alk2)p- wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.Type: ApplicationFiled: October 29, 2007Publication date: April 8, 2010Applicant: Chroma Terapeutics LtdInventors: David Festus Charles Moffat, Stephen John Davies, Michael Hugh Charlton, Simon Christopher Hirst, Stuart Thomas Onions, Jonathan Gareth Williams
-
Patent number: 6258840Abstract: Novel carbamate ester analogues or derivatives of Quercetin (prodrugs) are provided which have enhanced aqueous solubility and which are especially suitable for use as biodegradable prodrugs in pharmaceutical compositions formulated for clinical use.Type: GrantFiled: July 20, 1999Date of Patent: July 10, 2001Assignee: Cobra Therapeutics LimitedInventors: Bernard Thomas Golding, Roger John Griffin, Charmaine Paulina Quarterman, John Alfred Slack, Jonathan Gareth Williams
-
Patent number: 5985913Abstract: The present invention provides a compound in substantially pure form having the structure: ##STR1## wherein each of R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, and R.sub.8 may independently be hydrogen, halogen, nitro, CF.sub.3, hydroxy, C.sub.1-5 alkyl, aryl or OR.sub.9, wherein R.sub.9 is C.sub.1-5 alkyl, wherein R.sub.10 is COC.sub.1-5 alkyl; or wherein any two consecutive R groups may be members of a C.sub.5 -C.sub.6 membered ring, and wherein the intracyclic-dashed line represents a covalent bond which may be present or absent, with the proviso that when R.sub.10 is present, the exocyclic-covalent bond is absent, and when R.sub.10 is absent, the exocyclic-covalent bond is present, and with the proviso that when R.sub.10 is absent, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, and R.sub.8 cannot all be hydrogen and when R.sub.10 is absent, R.sub.5, R.sub.6, R.sub.7, and R.sub.8 cannot all be hydrogen when either R.sub.1, R.sub.2, R.sub.3, or R.sub.Type: GrantFiled: April 29, 1998Date of Patent: November 16, 1999Assignee: OSI Pharmaceuticals, Inc.Inventors: Jonathan Gareth Williams, David R. Houck, David Edward Smith, Daniel Lee Rathbone, David Charles Billington, Bernard T. Golding, Eric W. Collington, John Kitchin, Nicholas Rich